ABSTRACT-Null genotype of glutathione S-transferase class m (GSTM1(-)) and the plasma level of malondialdehyde (MDA) were determined in normal subjects, epileptics with good seizure control and epileptics with intractable seizure. The frequency of GSTM1(-) of the epileptics with intractable seizure was significantly higher than that of the group with good seizure control and that of the normal subjects. The average plasma level of MDA of the patients with GSTM1(-) genotype was higher than that of the subjects with GSTM1(+) in either the normal or epileptic group. Thus, the GSTM1(-) genotype may be one of the genetic factors involved in the response to anticonvulsant therapy.
High-dose conventional anticonvulsants with multi-drug combinations were used to treat chronic complex partial seizure, but 68% of epileptics remained unresponsive or their condition became more exacerbated (1) . In 1995, it was observed that poly-anticonvulsants therapy in the patients with intractable seizure could induce profound lipid peroxidation caused by enhanced free radical generation (2) . High oxidative stress may halt or counteract the pharmacological effect of anticonvulsants including the poly-anticonvulsants therapy. Many conventional anticonvulsants have been proved to generate active metabolites via the cytochrome P450 system, including carbamazepine, phenytoin and phenobarbital (3) . These metabolites of poly-anticonvulsants are harmful to tissue cells including the fetus organs during pregnancy, if they are not quickly disposed of by the detoxification system and free radical scavenging enzymes (3, 4) . In our previous studies, increase of oxidative stress and disturbance of antioxidants homeostasis, which may contribute to the fetal hydantoin syndrome, were noted in the epileptic patients receiving phenytoin therapy (5, 6) . Moreover, it was reported that activities of scavenging enzymes for reactive oxygen species, including glutathione S-transferase (GST), were decreased in the patients with intractable seizure (2) . GST belongs to a family of phase II detoxification enzymes catalyzing the conjugation of glutathione to electrophilic compounds, including metabolites of anticonvulsants. Moreover, the existence of null genotype of GST m class (GSTM1(-)) may result in the low activity of GST due to poor expression of GSTM1, and low capacity of drug detoxification may result in oxidative damage including lipid peroxidation and DNA damage that are involved in carcinogenesis (7) . Therefore, we have hypothesized that the epileptic patients with GSTM1(-) genotype may contribute to the enhanced lipid peroxidation and poor drug response to anticonvulsants therapy. In this study, we examined the allele frequency of GSTM1(-) and plasma malondialdehyde (MDA), an index of lipid peroxidation, in normal subjects and epileptic patients with good seizure control or intractable seizure.
Informed consent for study enrollment was obtained from each of the recruited subjects. All of the human experimental procedures followed the ethical standards of Changhua Christian Hospital. We selected 97 epileptics with good seizure control by mono-anticonvulsant therapy and 35 epileptics with intractable seizure by poly-anticonvulsants therapy. A total of 1191 healthy subjects were also included as normal controls. Seizure control was judged to be good if the seizure frequency of epileptics was less than 2 times /month under mono-anticonvulsant therapy. Intractable seizure was defined as the seizure frequency being greater than 4 times /month with adequate combination of anticonvulsants therapy and effectively monitoring therapeutic levels of anticonvulsants for four months. The kinds of anticonvulsants listed included phenytoin, carbamazepine, valproic acid, and phenobarbital (Table 1) . Only the epileptics with generalized tonic clonic convulsion or focal seizure with secondary generalization were enrolled in this study (Table 1 ). All patients and normal controls were selected at the Neurologic Clinic of Changhua Christian Hospital and Kuang Tien General Hospital. From each subject, 10 ml of whole blood was withdrawn from an antecubital vein and transferred to a heparin-containing blood sampling tube. Plasma was immediately collected by centrifugation and divided into several aliquots and stored at -80°C in metal-free plastic tubes. MDA level in the plasma was determined within 3 days. None of the patients had received blood sampling within one week after seizure since it may interfere with the level of plasma lipid peroxide. Lipid peroxides in plasma were determined as MDA by HPLC, and the amount of MDA in the plasma was calculated from a calibration curve and expressed as mM (8) . The GSTM1 genotype was determined by using a PCR method with double genes co-amplified in the same tube. An aliquot of 10 -100 ng DNA was added to a PCR mixture containing 30 pmol of each primer for GSTM1 gene (G5-5' GAA CTC CCT GAA AAG CTA AAG C-3'; G6-5' GTT GGG CTC AAA TAT ACG GTG G-3'), 10 pmol of b-globin gene primers (PC04-5' CAA CTT CAT CCA CGT TCA CC-3'; GH20-5' GAA GAG CCA AGG ACA GGT AC-3'), 200 mmol deoxyribonucleoside triphosphates, 1 U Taq DNA polymerase and 10´ PCR buffer (10 mM Tris-HCl, pH 8.8 at 25°C, 1.5 mM MgCl2, 50 mM KCl and 0.1% Triton X-100) in a final volume of 30 ml. The reaction mixture was placed in a Perkin-Elmer 480 DNA thermal cycler for 3 min at 94°C and then subjected to 24 cycles of 94°C for 10 s, 57°C for 20 s, and 72°C for 45 s. This was followed by a final step at 72°C for 5 min. PCR products from co-amplification of GSTM1 (216 bp) and b-globin (268 bp) genes were resolved on an ethidium bromidestained 4% NuSieve /agarose (3:1) gel (FMC Bioproducts, Rockland, ME, USA). A segment of b -globin gene was coamplified as internal positive control in the PCR reaction. The null and non-null genotypes of GSTM1 (GSTM1(-) /GSTM1(+)) were determined by the absence and presence, respectively, of a 215-bp DNA fragment (9) (Fig. 1) . GSTM1(-) represents the absence of GSTM1 expression in either allele and is also indicated as the homozygous null genotype. GSTM1(+) represents the existence of one or two GSTM1-expressing alleles and is also indicated as the homozygous positive genotype or heterozygous genotype.
Allele frequencies of GSTM1(-) and the plasma levels of MDA of the normal control and patients with good seizure control and intractable seizure were statistically analyzed. The allele frequencies of the GSTM1(-) genotype in the 3 groups were compared by using the Chisquare test. One-way ANOVA was used to compare the plasma levels of MDA of the subjects in different groups.
The GSTM1(-) genotype, plasma MDA, and seizure frequency of all the studied subjects are summarized in Table 2 . The allele frequency of the GSTM1(-) genotype of the epileptics with intractable seizure was significantly higher than those of the epileptics with good seizure control (80.0% vs 48.5%, OR = 4.3, P = 0.001) and healthy subjects (80.0% vs 49.5%, OR = 4.1, P = 0.001). In contrast, no significant difference in the GSTM1(-) frequency was found between patients with good seizure control and normal healthy subjects (48.5% vs 49.5%, OR = 0.9, P = 0.850). In the group of intractable seizure, plasma MDA of the patients with the GSTM1(-) genotype was higher than that of the GSTM1(+) epileptics (3.4 ± 1.8 mM vs 2.3 ± 0.9 mM, P = 0.011) with intractable seizure under poly-anticonvulsants treatment. However, no difference in the plasma MDA level was found between subjects with GSTM1(+) genotype and subjects with GSTM1(-) genotype in the group of normal healthy subjects (1.7 ± 0.5 mM vs 2.1 ± 1.3 mM, P = 0.067) and in the group of epileptics with good seizure control (2.4 ± 0.9 mM vs 2.6 ± 0.8 mM, P = 0.547).
Many conventional anticonvulsants are metabolized to generate active metabolites including epoxides (3). Therefore, the anticonvulsants may not only have effect on the suppression of epileptic spike, but also have systemic toxicity via epoxide-induced covalent binding to proteins and lipids. Lipid peroxidation, which has been proved to be an etiological factor of post-traumatic seizures, may promote the deterioration of seizure control even under treatment with poly-anticonvulsants (2, 10). The enzyme activity of GST, one group of the detoxification enzymes with polymorphic genotypes, plays a vital role in the detoxification of the electrophilic xenobiotics, especially in the removal of epoxide metabolites that are generated during the metabolism of conventional anticonvulsants (11) . Moreover, many detoxification enzymes in the superfamily of GST including GSTM are present in neurons, astrocytes, and Purkinji cells. In addition, the GST induction is suspected to be associated with the response of malignant astrocytoma to chemotherapy (12) . Individuals lacking GSTM1 isoenzyme activity due to a homozygous deletion in the GSTM1 gene, and therefore having a GSTM1(-) genotype, may have altered capacity of protecting tissues from exogenous and endogenous oxidants, including metabolites of anticonvulsants (13) . The frequency of GSTM1(-) in normal population of Caucasians has been reported to be 40 -50%. In the present study, the similar incidence of GSTM1(-), compared with Caucasian population, was noted in our normal subjects and the patients with good seizure control. Nevertheless, high incidence of GSTM1(-) genotype was noted in patients with intractable seizure. This observation may indicate that defect of GSTM1 gene expression in patients with GSTM1(-) genotype may contribute to the overt drug response of epileptics with intractable seizure. Furthermore, elevated plasma MDA may indicate enhanced lipid peroxidation of polyunsaturated fatty acids or excessive production of active metabolites of anticonvulsant formed in the plasma of epileptic patients. The aforementioned observations and inferences suggest that the GSTM1(-) genotype may be a susceptible genetic factor involved in the response of epileptic patients receiving anticonvulsant therapy.
In conclusion, we have demonstrated in the present study that the plasma lipid peroxides (MDA) are elevated in the epileptic patients with intractable seizure who bear the GSTM1(-) genotype and receive anticonvulsant therapy. c vs normal control in the comparison of GSTM1 allele frequency (OR = 0.9, P = 0.850). d vs GSTM1(+) group of epileptics with intractable seizure in the comparison of levels of MDA, P = 0.011.
e vs GSTM1(+) group of epileptics with good seizure control in the comparison of levels of MDA, P = 0.547.
f vs GSTM1(+) group of normal control in the comparison of levels of MDA, P = 0.067.
g Mean ± S.D.
Further work is warranted to determine whether the gene of GST, or the genes of other antioxidant enzymes, is involved in the response of epileptic patients receiving different therapeutic treatments.
